Shares of BeOne Medicines (ONC) are soaring 5.07% in pre-market trading on Thursday, following the company's impressive third-quarter earnings report and raised full-year guidance. The biotechnology firm, also known as BEIGENE, has demonstrated robust growth across its product portfolio, particularly with its flagship drug BRUKINSA.

BeOne Medicines reported adjusted earnings of $1.09 per share for the quarter ended September 30, significantly beating the analysts' consensus estimate of 78 cents per share. Revenue surged 41% year-over-year to $1.41 billion, surpassing the expected $1.36 billion. The strong performance was primarily driven by BRUKINSA's global sales, which reached RMB 7.423 billion in Q3, a 51.0% increase from the previous year.

Buoyed by these results, BeOne Medicines raised its full-year 2025 revenue guidance to RMB 36.2–38.1 billion, up from the previous forecast of RMB 35.8–38.1 billion. This optimistic outlook is supported by BRUKINSA's leading position in the U.S. market and its continued expansion in Europe and other key regions. Additionally, the company's pipeline is progressing well, with 20 critical milestones expected within the next 18 months, including advancements in hematology, solid tumors, and immunology treatments. This robust pipeline and strong financial performance have reinforced investor confidence in BeOne Medicines' growth trajectory, contributing to today's stock surge.